China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ). China NT Pharma Group has issued a supplemental announcement detailing judicial procedure records involving director and chairman Ng Tit, arising from his role as legal representative of former subsidiary Jiangsu Tailing Investment. The matter stems from a RMB119 million loan dispute secured by real estate owned by Suzhou First Pharmaceutical, which led to a consumption restriction order against Jiangsu Tailing and corresponding restrictions on Mr. Ng under PRC law. Following the commencement of bankruptcy reorganization proceedings for Suzhou First Pharmaceutical, the secured creditor China Merchants Bank’s Suzhou branch was repaid in full from the collateral, and the relevant enforcement case has been folded into the reorganization and fully settled. The company emphasized that these records are linked to corporate guarantees rather than any personal misconduct by Mr. Ng and stated that the issues are not expected to materially affect the Group’s daily operations, financial position, or Mr. Ng’s ability to serve as a director. More about China NT Pharma Group Co., Ltd. China NT Pharma Group Co., Ltd. is a pharmaceutical company listed in Hong Kong that operates through various subsidiaries in mainland China. The Group’s activities include drug-related operations and investments, with entities such as Suzhou First Pharmaceutical Co., Ltd. and formerly Jiangsu Tailing Investment Co., Ltd. forming part of its corporate structure. Average Trading Volume: 317,450 Technical Sentiment Signal: Sell Current Market Cap: HK$597.9M For an in-depth examination of 1011 stock, go to TipRanks’ Overview page.